ClinicalTrials.gg
CompletedNCT05631860Updated Dec 5, 2022

Psychological Risk Factors for Functional Somatic Disorders

An observational study in Irritable Bowel Syndrome, Fibromyalgia and Chronic Fatigue Syndrome, sponsored by University of Aarhus. Completed. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2022-12-05.

Sponsored by University of Aarhus · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,493
Ages
18 Years to 84 Years
Sex
All
01

Study summary

The objective of this study is to explore the role of neuroticism, perceived stress, and adverse life events, respectively, in the development and perpetuation of functional somatic disorders.

Read the detailed description

Functional somatic disorders (FSD) are common disorders with a multifactorial aetiology involving biological, social, and psychological factors. An often used explanation of the illness mechanisms behind FSD which is provided to the patients is, that FSD may be understood as a multi systemic physical response to stress. This relationship can be modelled as proposed in the Cognitive Behavioural Therapy (CBT) model of emotional distress where several cognitive, behavioural and psychological factors are thought to contribute to the onset and perpetuation of FSD. Personality traits e.g. neuroticism contribute to give rise to our cognitive, behavioural, and psychological reactions. Furthermore, neuroticism with its heightened reactivity to stressors, has shown to be an important predictor of a generic vulnerability to both physical and psychological conditions. Having been exposed to previous adverse life events/traumas and childhood adversities has also showed to impact the risk of having FSD. This relationship has been proposed to be induced by a heightened response to stimuli, i.e. sensitisation, caused by physical and emotional distress triggering a hormonal cascade in the hypothalamus pituitary adrenal (HPA) axis.

So far, most studies into these aspects have been carried out in selected patient samples, and general population-based studies including a large randomly obtained sample are sparse. In three recent population-based studies, strong associations between FSD and neuroticism, perceived stress, and the accumulated number of experienced adverse life events (ALE), respectively, have been established. However, these studies were cross-sectional, thereby not providing insight to whether these factors were risk factors of FSD. More studies are needed for further elucidation on these aspects.

Objective The objective of this study is to explore the role of neuroticism, perceived stress, and the accumulated number of ALE, respectively, in the development and perpetuation of FSD.

Hypotheses

  1. Higher neuroticism, higher perceived stress, and higher number of ALE at baseline are individual risk factors of having developed FSD in the 5-year period from baseline to follow-up:

    FSD non-case at baseline → FSD case at follow-up

  2. Neuroticism, perceived stress, and the accumulated number of ALE positively contribute to the perpetuation of FSD from baseline to follow-up:

FSD case at baseline → FSD case at follow-up

Analytical plan All analyses will be performed using STATA version 17.0. Descriptive statistics will be presented for all the three continuous explanatory variables across FSD diagnoses. Depending on data distribution, descriptive statistics will be presented as means and standard deviations or medians and interquartile ranges.

Depending on number of incident and perpetuating cases at follow-up, a range of analyses will be conducted with the purpose of investigating if higher neuroticism, higher perceived stress, and higher accumulated number of ALE at baseline

  1. are individual risk factors for the development of FSD from baseline to follow-up
  2. are positively contributing to the perpetuation of an FSD from baseline to follow-up

The first choice of analyses For hypothesis one, multiple logistic regression models will be performed with incident FSD cases at follow-up as primary outcome and baseline neuroticism, perceived stress, and accumulated number of ALE as explanatory primary variables. The effect of neuroticism, perceived stress, and the accumulated number of ALE will be reported from the same analysis as the effect when controlled for the effect from the other primary explanatory variables. Odds ratio (OR) with 95% confidence intervals (CI) will be used as measure of association; an OR > 1 supports the hypothesis. The reference group will constitute participants without FSD at both baseline and follow-up. Reference value of neuroticism, perceived stress, and the accumulated number of ALE will be set as the median value of the total sample. In each analysis there will be controlled for the confounding effect of sex (with male as reference) and age (the median value of the total sample).

For hypothesis two, multiple logistic regression models will be performed with FSD cases perpetuating from baseline to follow-up as primary outcome and baseline neuroticism, self-perceived stress, and accumulated number of ALE as primary explanatory variable. The effect of neuroticism, perceived stress, and the accumulated number of ALE will be reported from the same analysis as the effect when controlled for the effect from the other primary explanatory variables. Odds ratio (OR) with 95% confidence intervals (CI) will be used as measure of association; an OR > 1 supports the hypothesis. The reference group will constitute participants with FSD at baseline but without FSD at follow-up. Reference value of neuroticism, perceived stress, and the accumulated number of ALE will be set as the median value of the total sample. In each analysis there will be controlled for the confounding effect of sex (with male as reference) and (the median value of the total sample).

The second choice of analyses

If number of incident and perpetuated cases at follow-up are too low to perform the above multiple logistic regression models with incorporation of the three primary explanatory variables in one analyses per FSD definition, it will be investigated if the confounding primary explanatory variables can be reduced into one variable and incorporated in separate analyses instead. Hence, instead of performing one analysis per FSD definition, three logistic regression analyses will be performed for each FSD definition:

  1. An analysis investigating the effect of baseline neuroticism (primary explanatory variable) as risk factor for incident FSD/contributor to perpetuating FSD (primary outcome) with adjustment for 1) perceived stress and the accumulated number of ALE reduced into one variable, 2) sex, and 3) age.
  2. An analysis investigating the effect of baseline perceived stress (primary explanatory variable) as risk factor for incident FSD/contributor to perpetuating FSD (primary outcome) with adjustment for 1) neuroticism and the accumulated number of ALE reduced into one variable, 2) sex, and 3) age.
  3. An analysis investigating the effect baseline accumulated number of ALE (primary explanatory variable) as risk factor for incident FSD/contributor to perpetuating FSD (primary outcome) with adjustment for 1) neuroticism and perceived stress reduced into one variable, 2) sex, and 3) age.

To find out if the confounding primary explanatory variables can be reduced into one variable, principal component analyses will be performed.

The third choice of analyses If the second set of analyses cannot provide us with meaningful variables describing the primary explanatory variables, separate logistic regression analyses investigating the effect of neuroticism, perceived stress, and the accumulated number of ALE, respectively, will be performed with pre-defined prioritisation of confounders. The prioritisation will be as follows (depending on the primary explanatory variable): 1) neuroticism, 2) perceived stress, 3) accumulated number of ALE, 4) sex, and 5) age.

02

Conditions studied

  • Irritable Bowel Syndrome
  • Fibromyalgia
  • Chronic Fatigue Syndrome
  • Somatoform Disorders
  • Bodily Distress Syndrome
  • Medically Unexplained Symptoms
  • Medically Unexplained Syndrome
03

In context

Irritable Bowel Syndrome

1,116 studies on the registry are indexed under Irritable Bowel Syndrome; 208 are open to participants now.

This study's enrollment of 7,493 is above the median of 160 across 191 observational studies indexed under Irritable Bowel Syndrome.

Browse Irritable Bowel Syndrome studies →

Lead sponsor

University of Aarhus is the lead sponsor of 1,300 studies on the registry; 189 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

A total of 28773 participants were randomly drawn from the adult general Danish population by means of the the Danish Civil Registration system.

The DanFunD baseline cohort comprises a total of 9,656 (33.7% of invited participants) men and women aged 18-76 years, born in Denmark, and living in the Western part of greater Copenhagen.

The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • None

Exclusion criteria

Exclusion Criteria:

  • Not born in Denmark
  • Not being a Danish citizen
  • Pregnancy
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,493 participants (actual)
Patient registry
No

Groups and cohorts

  • DanFunD baseline

    The baseline cohort (gathered in the years 2012-2015) is a random sample selected through the National Civil Registration system among people living in 10 municipalities in the western part of greater Copenhagen, Denmark, ages 18 to 76 years. The baseline cohort constitutes data from self-reported questionnaires (n=7,493) and diagnostic interviews data (n=1,590).

  • DanFunD 5-years follow-up investigation

    The follow-up cohort (gathered in the years 2018-2020) consists of participants all born in Denmark, between 24 and 84 years of age. The follow-up cohort constitutes data from self-reported questionnaires (n=4,288) and diagnostic interviews data (n=1,094).

06

What researchers measure

Primary outcomes

  1. Questionnaire-defined Functional somatic disorder at baseline

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with self-reported questionnaires.

    Time frame: At the DanFunD baseline investigation

  2. Interview-based Functional somatic disorder at baseline

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with diagnostic interviews.

    Time frame: At the DanFunD baseline investigation

  3. Questionnaire-defined Functional somatic disorder at 5-year follow-up

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with self-reported questionnaires.

    Time frame: At the DanFunD 5-year follow-up investigation

  4. Interview-based Functional somatic disorder at 5-year follow-up

    Participants fulfilling the diagnostic criteria of the unifying diagnostic concept Bodily Distress Syndrome single- and multi-organ type will be defined with diagnostic interviews.

    Time frame: At the DanFunD 5-year follow-up investigation

  5. Irritable bowel at baseline

    Participants fulfilling the diagnostic criteria for irritable bowel will be identified with self-reported questionnaires

    Time frame: At the DanFunD baseline investigation

  6. Irritable bowel at 5-year follow-up

    Participants fulfilling the diagnostic criteria for irritable bowel will be identified with self-reported questionnaires

    Time frame: At the DanFunD 5-year follow-up investigation

  7. Chronic widespread pain at baseline

    Participants fulfilling the diagnostic criteria for chronic widespread pain will be identified with self-reported questionnaires

    Time frame: At the DanFunD baseline investigation

  8. Chronic widespread pain at 5-year follow-up

    Participants fulfilling the diagnostic criteria for chronic widespread pain will be identified with self-reported questionnaires.

    Time frame: At the DanFunD 5-year follow-up investigation

  9. Chronic fatigue at baseline

    Participants fulfilling the diagnostic criteria for chronic fatigue will be identified with self-reported questionnaires.

    Time frame: At the DanFunD baseline investigation

  10. Chronic fatigue at 5-year follow-up

    Participants fulfilling the diagnostic criteria for chronic fatigue will be identified with self-reported questionnaires.

    Time frame: At the DanFunD 5-year follow-up investigation

Other outcomes

  1. Neuroticism score at baseline

    Measured with the Danish version of the short-form NEO Personality Inventory (NEO-PI-Rsf). It includes 60 self-descriptive statements each rated with a five-point rating scale from "strongly disagree" to "strongly agree". For the domain neuroticism, a sum score of 12 items, each ranging from 12 to 60, is calculated and higher score indicates higher neuroticism.

    Time frame: Measured at baseline

  2. Perceived Stress score at baseline

    Measured with the Cohen's Perceived Stress Scale. It consists of 10 items each rated on a five-point rating scale from "never" to "very often". The sum score ranges from 0 to 40 and higher score indicates higher level of perceived stress.

    Time frame: Measured at baseline

  3. The accumulated number of adverse life events score at baseline

    Measured with the Danish version of the Cumulative Lifetime Adversity Measure (CLAM). CLAM obtains exposure to lifetime adversity by asking the respondents whether they have experienced 37 different adverse life events plus a possibility to add one other unnamed life event. For a positive answer to an event, a number of event score is calculated by adding age time-points and age ranges by simply counting age time-points and age ranges, i.e. an age range counted for one event and an age time-point counted for one event. The sum score ranging from 0 to 130 with higher score indicating higher number of adversities.

    Time frame: Measured at baseline

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Restrictions apply to the availability of data according to Danish law, which means that data cannot be made publicly available. A request for collaboration or access to data can be sent to ckff@regionh.dk. An application for data should consist of a short synopsis of the study planned. Please see our website (www. danfund.org) for more information.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05631860
Collaborators
Center for Clinical Research and Prevention
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Nov 10, 2011
Primary completion
Jan 4, 2021
Completion
Aug 30, 2022
Last update
Dec 5, 2022

Study contacts

Per Fink, DMSc
study chair · Aarhus University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion